Table 1

Demographics and baseline characteristics

Placebo
(N = 108)Dapagliflozin 10 mg/day
(N = 108)
Age, mean (SD), years60.9 (9.2)61.1 (9.7)
Female, n (%)48 (44.4)62 (57.4)
Race, n (%)
 White102 (94.4)104 (96.3)
Weight, mean (SD), kg90.1 (16.2)88.6 (17.6)
BMI, mean (SD), kg/m232.0 (4.6)31.9 (4.8)
SBP, mean (SD), mmHg136.4 (14.2)134.5 (12.6)
DBP, mean (SD), mmHg81.6 (7.9)80.4 (9.2)
Type 2 diabetes duration, mean (SD), years9.6 (6.2)9.3 (6.5)
HbA1c, mean (SD), % [mmol/mol]8.24 (0.87) [67 (9.5)]8.08 (0.91) [65 (9.9)]
FPG, mean (SD), mg/dL [mmol/L]180.2 (43.1) [10.00 (2.39)]167.4 (43.3) [9.29 (2.40)]
Prior history of cardiovascular disease, n (%)95 (88.0)91 (84.3)
Concomitant medications, n (%)
 Thiazide diuretics29 (26.6)30 (27.5)
 Antihypertensives95 (87.2)89 (81.7)
 Angiotensin receptor blocker and/or ACE83 (76.1)75 (68.8)
  • N is the number of patients in the full analysis set.